Sustained joint symptom relief proven for 2 years in PsA1
Fast2,3 and sustained complete clearance proven for 2 years in PsA1
Most patients who started on TREMFYA® stayed on TREMFYA® long-term1,4,5
Durability*, also known as patient retention or drug survival is a combination of efficacy, safety, tolerability and patient satisfaction or preference.
DISCOVER-2 was a Phase 3, double-blind, multi-centre, placebo-controlled study that evaluated the efficacy and safety of TREMFYA® in bio-naive patients with active PsA.1
TREMFYA®, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug therapy.6
TREMFYA® is indicated for adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy.6
Hear local and international Key Opinion Leaders discuss a variety of topics relating to rheumatology.
Resources and tools to help you provide your psoriatic arthritis patients with the information they need to understand their disease and treatment.
Keep up to the date with the ongoing events organised by our medical team.
Article 33 of Regulation (EC) No 1907/2006 REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) As required by Article 33 of REACH, Janssen, the Pharmaceutical Companies of Johnson & Johnson, informs that recipients of our articles are informed when our articles contain Substances of Very High Concern (SVHC) included in the Candidate List of REACH, in a concentration above 0.1 % weight by weight (w/w).
The following REACH SVHCs are present in the device constituent of Janssen products:
Product | Article containing Substance of Very High Concern | Substance of Very High Concern |
---|---|---|
ProductTremfya 100 mg solution for injection in pre-filled pen guselkumab | Article containing Substance of Very High Concernpre-filled pen – mid housing, needle guard and syringe retainer overmold | Substance of Very High Concern2-(2H-benzotriazol-2-yl)-4,6-ditertpentylphenol (UV-328)- CAS# 25973-55-1 |
More information on REACH can be found on the following websites:
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via: HPRA Pharmacovigilance Website: www.hpra.ie.
Adverse events should also be reported to Janssen Sciences Ireland UC on 1800 709 122 or at dsafety@its.jnj.com.